Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ABUS's Cash-to-Debt is ranked higher than
94% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. ABUS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ABUS' s Cash-to-Debt Range Over the Past 10 Years
Min: 7.35  Med: No Debt Max: No Debt
Current: No Debt
7.35
No Debt
Equity-to-Asset 0.86
ABUS's Equity-to-Asset is ranked higher than
80% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ABUS: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
ABUS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.03  Med: 0.76 Max: 0.9
Current: 0.86
0.03
0.9
Piotroski F-Score: 5
Altman Z-Score: 4.14
Beneish M-Score: 5.69
WACC vs ROIC
17.20%
-67.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -601.35
ABUS's Operating Margin % is ranked lower than
70% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. ABUS: -601.35 )
Ranked among companies with meaningful Operating Margin % only.
ABUS' s Operating Margin % Range Over the Past 10 Years
Min: -6726.49  Med: -89.16 Max: -30.9
Current: -601.35
-6726.49
-30.9
Net Margin % -511.06
ABUS's Net Margin % is ranked lower than
69% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. ABUS: -511.06 )
Ranked among companies with meaningful Net Margin % only.
ABUS' s Net Margin % Range Over the Past 10 Years
Min: -25765.53  Med: -106.25 Max: 209.93
Current: -511.06
-25765.53
209.93
ROE % -33.96
ABUS's ROE % is ranked higher than
55% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. ABUS: -33.96 )
Ranked among companies with meaningful ROE % only.
ABUS' s ROE % Range Over the Past 10 Years
Min: -126.54  Med: -42.82 Max: 128.39
Current: -33.96
-126.54
128.39
ROA % -24.18
ABUS's ROA % is ranked higher than
59% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ABUS: -24.18 )
Ranked among companies with meaningful ROA % only.
ABUS' s ROA % Range Over the Past 10 Years
Min: -77.75  Med: -33.9 Max: 89.33
Current: -24.18
-77.75
89.33
ROC (Joel Greenblatt) % -924.70
ABUS's ROC (Joel Greenblatt) % is ranked lower than
57% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. ABUS: -924.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABUS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9659.68  Med: -815.38 Max: -209.96
Current: -924.7
-9659.68
-209.96
3-Year Revenue Growth Rate -34.30
ABUS's 3-Year Revenue Growth Rate is ranked lower than
76% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ABUS: -34.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABUS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -69.7  Med: -9.6 Max: 237.1
Current: -34.3
-69.7
237.1
3-Year EBITDA Growth Rate -9.00
ABUS's 3-Year EBITDA Growth Rate is ranked lower than
65% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. ABUS: -9.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABUS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -26.8 Max: 11.6
Current: -9
0
11.6
3-Year EPS without NRI Growth Rate 4.70
ABUS's 3-Year EPS without NRI Growth Rate is ranked lower than
52% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. ABUS: 4.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABUS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -15.7 Max: 46.7
Current: 4.7
0
46.7
GuruFocus has detected 5 Warning Signs with Arbutus Biopharma Corp ABUS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABUS's 30-Y Financials

Financials (Next Earnings Date: 2018-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ABUS Guru Trades in Q3 2017

Steven Cohen 224,655 sh (New)
PRIMECAP Management 3,990,400 sh (+1.01%)
Jim Simons 160,610 sh (-23.61%)
» More
Q4 2017

ABUS Guru Trades in Q4 2017

Jim Simons 402,573 sh (+150.65%)
PRIMECAP Management 4,000,400 sh (+0.25%)
Steven Cohen Sold Out
» More
Q1 2018

ABUS Guru Trades in Q1 2018

PRIMECAP Management 4,000,400 sh (unchged)
Jim Simons 243,500 sh (-39.51%)
» More
Q2 2018

ABUS Guru Trades in Q2 2018

Pioneer Investments 23,400 sh (New)
Jim Simons 250,652 sh (+2.94%)
PRIMECAP Management 4,000,400 sh (unchged)
» More
» Details

Insider Trades

Financial Reports

8-K Current report
2018/06/07
8-K Current report
2018/05/23
8-K Current report
2018/05/03
8-K Current report
2018/04/30
8-K Current report
2018/04/12
8-K Current report
2018/04/11
8-K Current report
2018/03/28

Latest Guru Trades with NAS:ABUS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare:XKRX:001630, XKRX:200670, NAS:CBMG, NAS:SBBP, XPAR:COX, NAS:PRTK, NAS:COOL, NYSE:KDMN, XKRX:142760, NAS:NK, OTCPK:RCAR, ASX:SPL, NAS:MCRB, HKSE:08158, LSE:MPH, NAS:PIRS, XKRX:168330, SHSE:600556, WAR:MAB, NAS:CBIO » details
Traded in other countries:I9DN.Germany,
Headquarter Location:Canada
Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.

Arbutus Biopharma Corp is a pharmaceutical company. It discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.

Ratios

vs
industry
vs
history
PB Ratio 4.29
ABUS's PB Ratio is ranked lower than
52% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ABUS: 4.29 )
Ranked among companies with meaningful PB Ratio only.
ABUS' s PB Ratio Range Over the Past 10 Years
Min: 0.3  Med: 1.99 Max: 237.27
Current: 4.29
0.3
237.27
PS Ratio 41.36
ABUS's PS Ratio is ranked lower than
73% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ABUS: 41.36 )
Ranked among companies with meaningful PS Ratio only.
ABUS' s PS Ratio Range Over the Past 10 Years
Min: 0.72  Med: 5.57 Max: 190
Current: 41.36
0.72
190
EV-to-Revenue 40.10
ABUS's EV-to-Revenue is ranked lower than
68% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. ABUS: 40.10 )
Ranked among companies with meaningful EV-to-Revenue only.
ABUS' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.9  Med: 2.7 Max: 96.2
Current: 40.1
-1.9
96.2
Current Ratio 13.67
ABUS's Current Ratio is ranked higher than
85% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ABUS: 13.67 )
Ranked among companies with meaningful Current Ratio only.
ABUS' s Current Ratio Range Over the Past 10 Years
Min: 0.95  Med: 5.62 Max: 18.09
Current: 13.67
0.95
18.09
Quick Ratio 13.67
ABUS's Quick Ratio is ranked higher than
85% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. ABUS: 13.67 )
Ranked among companies with meaningful Quick Ratio only.
ABUS' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 5.62 Max: 18.09
Current: 13.67
0.95
18.09
Days Sales Outstanding 39.86
ABUS's Days Sales Outstanding is ranked higher than
72% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. ABUS: 39.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABUS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.76  Med: 23.17 Max: 66.83
Current: 39.86
2.76
66.83
Days Payable 18.39
ABUS's Days Payable is ranked lower than
80% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. ABUS: 18.39 )
Ranked among companies with meaningful Days Payable only.
ABUS' s Days Payable Range Over the Past 10 Years
Min: 11.57  Med: 19.16 Max: 22.81
Current: 18.39
11.57
22.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -34.90
ABUS's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. ABUS: -34.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABUS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -56.2  Med: -13.8 Max: 14.8
Current: -34.9
-56.2
14.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.33
ABUS's Price-to-Net-Cash is ranked higher than
67% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. ABUS: 4.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ABUS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.67  Med: 3.66 Max: 37.5
Current: 4.33
0.67
37.5
Price-to-Tangible-Book 14.00
ABUS's Price-to-Tangible-Book is ranked lower than
82% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. ABUS: 14.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ABUS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.59  Med: 3.48 Max: 165
Current: 14
0.59
165
Price-to-Median-PS-Value 7.40
ABUS's Price-to-Median-PS-Value is ranked lower than
96% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. ABUS: 7.40 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABUS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 1 Max: 29.55
Current: 7.4
0.17
29.55
Earnings Yield (Greenblatt) % -22.90
ABUS's Earnings Yield (Greenblatt) % is ranked lower than
73% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. ABUS: -22.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABUS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -48991.5  Med: -28.7 Max: 5523.4
Current: -22.9
-48991.5
5523.4

More Statistics

Revenue (TTM) (Mil) $12.11
EPS (TTM) $ -1.23
Beta2.56
Volatility72.91%
52-Week Range $3.45 - 12.60
Shares Outstanding (Mil)55.40

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}